Regístrese
Buscar en
Endocrinología y Nutrición
Toda la web
Inicio Endocrinología y Nutrición Hipercalcemia tumoral
Información de la revista
Vol. 51. Núm. 5.
Páginas 272-276 (Mayo 2004)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 51. Núm. 5.
Páginas 272-276 (Mayo 2004)
DOI: 10.1016/S1575-0922(04)74616-1
Acceso a texto completo
Hipercalcemia tumoral
Hypercalcemia of malignancy
Visitas
25318
M. Quesada
Autor para correspondencia
charneco@saludalia.com

Correspondencia: Dr. M. Quesada. Dr. Martín Lagos, 4, 7.° A. 18005 Granada. España.
, M. De La Higuera, D. Fernández, R. Reyes, M. Palma, P. Rozas, E. Quevedo, M. Muúoz, F. Escobar
Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Granada. Granada. España
Este artículo ha recibido
25318
Visitas
Información del artículo

Las neoplasias y el hiperparatiroidismo primario son las causas más frecuentes de hipercalcemia y comprenden el 90% de éstas. Hace casi medio siglo que se describió el síndrome de la hipercalcemia humoral tumoral y 15 años que se identificó su agente etiológico, la proteína relacionada con la paratirina (PTHrP), y se introdujo su medida en la práctica clínica y de investigación. El desarrollo de la hipercalcemia humoral tumoral constituye un signo de mal pronóstico. Disponemos de nuevos y potentes fármacos hipocalcemiantes (fundamentalmente bifosfonatos) para el tratamiento de estas situaciones, lo que permite a los pacientes mejorar su calidad de vida en fases a menudo terminales de la enfermedad.

Palabras claves:
Hipercalcemia
Hiperparatiroidismo primario
Cáncer
Bifosfonato

Malignancy and primary hyperparathyroidism are the most common causes of hypercalcemia, accounting for more than 90% of hypercalcemic patients. It has been half a century since humoral hypercalcemia of malignancy was first described and fifteen years since its etiological agent (PTHrP) was identified and introduced into medical and research activities. Humoral hypercalcemia of malignancy appears to be an ominous prognostic sign. New and potent anti-hypercalcemic agents (mainly bisphosphonates) are available to treat these situations allowing the patients to be in less discomfort during the terminal stage of their illness.

Key words:
Hypercalcemia
Primary hyperparathyroidism
Malignancy
Bisphosphonate
El Texto completo está disponible en PDF
Bibliografía
[1.]
E.M. Brown.
Homeostatic mechanism regulating extracellular and intracellular calcium metabolism.
The parathyroids, pp. 15-54
[2.]
A. Raya, Y. Kawakami, C. Rodríguez-Esteban, M. Ibáñez, D. Rasskin-Gutman, J. Rodríguez-León, et al.
Notch activity acts as a sensor for extracellular calcium during vertebrate left-right determination.
Nature, 427 (2004), pp. 121-128
[3.]
D. Pietrobon, F. Di Virgilio, T. Pozzan.
Structural and functional aspects of calcium homeostasis in eukaryotic cells.
Eur J Biochem, 120 (1990), pp. 599-622
[4.]
S.M. Kobrin, S. Goldfarb.
Hypocalcemia and hypercalcemia.
Acid-base and electrolyte disorders, pp. 169-196
[5.]
D.A. Bushinsky, R.D. Monk.
Calcium.
Lancet, 352 (1998), pp. 306-311
[6.]
E. Shane.
Hypercalcemia: pathogenesis, clinical manifestations, and differential diagnosis.
Primer on the metabolic bone diseases and disorders of mineral metabolism, pp. 153-163
[7.]
R.A. Fisken, D.A. Heath, S. Somers, A.M. Bold.
Hypercalcaemia in hospital patients; clinical and diagnostic aspects.
Lancet, 1 (1981), pp. 202-207
[8.]
J.P. Bilezikian, F.R. Singer.
Acute management of hypercalcemia due to parathyroid hormone and parathyroid hormone-related protein.
The parathyroids, pp. 359-372
[9.]
S.R. Nussbaum.
Pathophysiology and management of severe hypercalcemia.
pp. 343-362
[10.]
H.J. Kaminsky, R.L. Ruff.
Neurologic complications of endocrine diseases.
Clin Neurol, 7 (1989), pp. 493-495
[11.]
T.J. Rosol, C.C.S.O. Capen.
Mechanisms of cancer-induced hypercalcemia.
Lab Invest, 67 (1992), pp. 680-702
[12.]
M. Pecherstorfer, T. Schilling, E. Blind, I. Zimmer-Roth, G. Baumgartner, R. Ziegler, et al.
Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients.
J Clin Endocrinol Metab, 78 (1994), pp. 1268-1270
[13.]
A.B. Gutman, T.L. Tyson, E.B. Gutman.
Serum calcium, inorganic phosphorus and phosphatase activity in hyperparathyroidism, Paget's disease, multiple mieloma and neoplastic disease of the bones.
Arch Intern Med, 57 (1936), pp. 379-383
[14.]
G.R. Mundy.
Hypercalcemia in hematologic malignancies and in solid tumors associated with extensive localized bone destruction.
Primer on the metabolic bone diseases and disorders of mineral metabolism, pp. 173-176
[15.]
R. Torres, C. De la Piedra, A. Rapado.
Osseous and intestinal compartments in the humoral hypercalcemia of malignancy associated to Walker 256 tumor rats.
Oncology, 50 (1993), pp. 148-152
[16.]
T.J. Martin, L.J. Suva.
Parathyroid hormone-related protein in hypercalcaemia of malignancy.
Clin Endocrinol (Oxf), 31 (1989), pp. 631-647
[17.]
A.F. Stewart.
Humoral hypercalcemia of malignancy.
Primer on the metabolic bone diseases and disorders of mineral metabolism, pp. 169-173
[18.]
F. Albright.
Case records of the Massachusetts General Hospital.
N Engl J Med, 225 (1941), pp. 789-791
[19.]
F.W. Lafferty.
Pseudohyperparathyroidism.
Medicine, 45 (1966), pp. 247-260
[20.]
W.J. Burtis, T. Wu, C. Bunch, J.J. Wysolmerski, K.L. Insogna, E.C. Weir, et al.
Identification of a novel 17,000-dalton parathyroid hormone-like adenylate cyclase-stimulating protein from a tumor associated with humoral hypercalcemia of malignancy.
J Biol Chem, 262 (1987), pp. 7151-7156
[21.]
A.F. Stewart, T. Wu, D. Goumas, W.J. Burtis, A.E. Broadus.
N-terminal amino acid sequence of two novel tumor-derived adenylate cyclase-stimulating proteins: identification of parathyroid hormone-like and parathyroid hormone-unlike domains.
Biochem Biophy Res Commun, 146 (1987), pp. 672-678
[22.]
J.M. Moseley, M. Kubota, H.D. Diefenbach-Jagger, R.E.H. Wettenhall, B.E. Kemp, L.J. Suva, et al.
Parathyroid hormone-related protein purified from a human lung cancer line.
Proc Natl Acad Sci U S A, 84 (1987), pp. 5048-5052
[23.]
G.J. Strewler, P.H. Stern, J.W. Jacobs, J. Eveloff, R.F. Klein, S.C. Leung, et al.
Parathyroid hormone-like protein from human renal carcinoma cells: structural and functional homology with parathyroid hormone.
J Clin Invest, 80 (1987), pp. 1803-1807
[24.]
E.C. Weir, K.L. Insogna, D.G. Brownstein, N. Bander, A.E. Broadus.
In vitro adenylate cyclase-stimulating activity predicts the ocurrence of humoral hypercalcemia of malignancy in nude mice.
J Clin Invest, 81 (1988), pp. 818-821
[25.]
S.A. Rabbani, J. Mitchell, D.R. Roy, G.N. Hendy, D. Goltzman.
Influence of the amino-terminus on in vitro and in vivo biological activity of synthetic parathyroid hormone-like peptides of malignancy.
Endocrinology, 123 (1988), pp. 2709-2713
[26.]
G.J. Strewler, A.A. Budayr, O.H. Clark, R.A. Nissenson.
Production of parathyroid hormone by a malignant nonparathyroid tumor in a hypercalcemic patient.
J Clin Endocrinol Metab, 76 (1993), pp. 1373-1375
[27.]
J.J. Orloff, D. Reddy, A.E. De Papp, K.H. Yang, N.E. Soifer, A.F. Stewart.
Parathyroid hormone-related protein as a prohormone: posttranslational processing and receptor interactions.
Endocr Rev, 15 (1994), pp. 40-60
[28.]
L.E. Mallette.
The parathyroid polyhormones: new concepts in the spectrum of peptide hormone action.
Endocr Rev, 12 (1991), pp. 110-117
[29.]
Quesada-Charneco, M. Munoz-Torres, E. Jodar, F. Navarro-Pelayo, J.A. Lopez, I. Morales, et al.
Hipercalcemia aguda sintomatica: utilidad de la determinacion de la proteina relacionada con la parathormona (PTHrP).
Endocrinol Nutr, 42 (1995), pp. 193-196
[30.]
M.W. Savage, W.D. Fraser, C.W. Bodmer, A.F. Ginty, J.A. Gallagher, J. Robinson, et al.
Hypercalcaemia due to parathyroid hormone-related protein: long-term circulating levels may not reflect tumour activity.
Clin Endocrinol (Oxf), 39 (1993), pp. 695-698
[31.]
W.J. Burtis, T.G. Brady, J.J. Orloff, J.B. Ersbak, R.P. Warrell Jr, B.R. Olson, et al.
Inmunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer.
N Engl J Med, 322 (1990), pp. 1106-1112
[32.]
J.M. Moseley, J.A. Hayman, J.A. Danks, D. Alcorn, V. Grill, J. Southby, et al.
Immunohistochemical detection of parathyroid hormone-related protein in human fetal epithelia.
J Clin Endocrinol Metab, 73 (1991), pp. 478-484
[33.]
N.J. Bundred, W.A. Ratcliffe, R.M. Walker, S. Coley, J.M. Morrison, J.G. Ratcliffe.
Parathyroid hormone related protein and hypercalcaemia in breast cancer.
BMJ, 303 (1991), pp. 1506-1509
[34.]
A.E. De Papp, A.F. Stewart.
Parathyroid hormone-related protein. A peptide of diverse physiologic functions.
Trends Endocrinol Metab, 4 (1993), pp. 181-187
[35.]
C.P. Rodda, M. Kubota, J.A. Heath, P.R. Ebeling, J.M. Moseley, A.D. Care, et al.
Evidence for a novel parathyroid hormone-related protein in fetal lamb parathyroid glands and sheep placenta: comparisons with a similar protein implicated in humoral hypercalcaemia of malignancy.
J Endocrinol, 117 (1988), pp. 261-271
[36.]
M. Iwase, T. Takemi, M. Manabe, M. Nagumo.
Hypercalcemic complication in patients with oral squamous cell carcinoma.
Int J Oral Maxillofac Surg, 32 (2003), pp. 174-180
[37.]
M. Munoz-Torres, M. Quesada-Charneco, E. Jodar, F. Escobar-Jimenez.
Valoracion de la calcitonina nasal e inyectable en la osteoporosis postmenopausica.
Rev Esp Enf Metab Oseas, 3 (1994), pp. 9-11
[38.]
J.C. Dumon, A. Magritte, J.J. Body.
Nasal human calcitonin for tumor-induced hypercalcemia.
Calcif Tissue Int, 51 (1992), pp. 18-19
[39.]
A. Carano, S.L. Teitelbaum, J.D. Konsek, P.H. Schlesinger, H.C.S.O. Blair.
Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro.
J Clin Invest, 85 (1990), pp. 456-461
[40.]
R.E. Coleman.
Skeletal complications of malignancy.
Cancer, (1997), pp. 1588-1594
[41.]
J. Green, K. Muller, K.A. Jaeggi.
Preclinical pharmacology of CGP 42,446, a new, potent, heterocyclic bisphosphonate compound.
J Bone Miner Res, 9 (1994), pp. 745-751
[42.]
K. Wellington, K.L. Goa.
Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy.
Drugs, 63 (2003), pp. 417-437
[43.]
Chitambar CRSO.
Gallium nitrate revisited.
Semin Oncol, 30 (2003), pp. 1-4
[44.]
W.S. Koo, D.S. Jeon, S.J. Ahn, Y.S. Kim, Y.S. Yoon, B.K.S.O. Bang.
Calcium-free hemodialysis for the management of hypercalcemia.
Nephron, 72 (1996), pp. 424-428
[45.]
K. Nosaka, T. Miyamoto, T. Sakai, H. Mitsuya, T. Suda, M. Matsuoka.
Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaβ ligand on adult T-cell leukemia cells.
Blood, 99 (2002), pp. 634-640
[46.]
B.O. Oyajobi, D.M. Anderson, K. Traianedes, P.J. Williams, T. Yoneda, G.R. Mundy.
Therapeutic efficacy of a soluble receptor activator of nuclear factor kappa β-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy.
Cancer Res, 61 (2001), pp. 2572-2578
[47.]
K. Endo, K. Katsumata, H. Iguchi, N. Kubodera, T. Teramoto, K. Ikeda, et al.
Effect of combination treatment with a vitamin D analog (OCT) and a bisphosphonate (AHPrBP) in a nude mouse model of cancer-associated hypercalcemia.
J Bone Miner Res, 13 (1998), pp. 1378-1383
[48.]
S.C. Kukreja, D.H. Shevrin, S.A. Wimbiscus, P.R. Ebeling, J.A. Danks, C.P. Rodda, et al.
Antibodies to parathyroid hormone-related protein lowers serum calcium in athymic mouse models of malignancy-associated hypercalcemia due to human tumors.
J Clin Invest, 82 (1988), pp. 1798-1802
[49.]
T. Michigami, H. Yamato, H. Suzuki, Y. Nagai-Itagaki, K. Sato, K. Ozono.
Conflicting actions of parathyroid hormone-related protein and serum calcium as regulators of 25-hydroxyvitamin D(3)-1 alpha-hydroxylase expression in a nude rat model of humoral hypercalcemia of malignancy.
J Endocrinol, 171 (2001), pp. 249-257
[50.]
J.L. Motellon, F. Javort Jimenez, F. De Miguel, M.J. Jaras, A. Diaz, J. Hurtado, et al.
Parathyroid hormone-related protein, parathyroid hormone, and vitamin D in hypercalcemia of malignancy.
Clin Chim Acta, 290 (2000), pp. 189-197
Copyright © 2004. Sociedad Española de Endocrinología y Nutrición
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.